Vulvovaginal candidiasis
Pro Research Analysisby 
Searched over 200M research papers for "vulvovaginal candidiasis"
Epidemiology and Prevalence of Vulvovaginal Candidiasis
Vulvovaginal candidiasis (VVC) is a very common infection, affecting up to 75% of women of reproductive age at least once in their lifetime, with about 5–10% experiencing recurrent episodes (RVVC) Brocklebank2013Gonçalves2016MacAlpine2024+1 MORE. The condition is most prevalent among healthy, immunocompetent women, especially during their childbearing years Willems2020Sustr2020Gonçalves2016.
Causes and Risk Factors for Vulvovaginal Candidiasis
The main cause of VVC is the overgrowth of Candida species, particularly Candida albicans, though non-albicans species like Candida glabrata are increasingly recognized Willems2020Sustr2020Gonçalves2016+1 MORE. Several factors can increase the risk of developing VVC, including pregnancy, diabetes, immunosuppression, antibiotic use, hormone replacement therapy, and genetic predispositions Brocklebank2013Gonçalves2016Sobel1987+1 MORE. Behavioral factors such as use of oral contraceptives, intrauterine devices, spermicides, condoms, and certain hygiene or sexual practices also contribute to risk Gonçalves2016Lines2020.
Pathogenesis and Host Response in Vulvovaginal Candidiasis
VVC is characterized by an imbalance between Candida colonization and the host environment, often triggered by physiological or external changes Willems2020Gonçalves2016. The disease is marked by pathologic inflammation, with symptoms largely driven by immune responses, particularly neutrophil-associated dysfunction Willems2020MacAlpine2024. Unlike other forms of candidiasis, VVC typically affects otherwise healthy women Willems2020Sustr2020.
Clinical Presentation and Diagnosis of Vulvovaginal Candidiasis
Typical symptoms include vulval itching, soreness, non-offensive vaginal discharge (often curd-like but sometimes thin or absent), and superficial pain during intercourse . Diagnosis relies on clinical assessment and, when necessary, laboratory tests to confirm the presence and type of Candida species Sustr2020Sobel1998Lines2020. Fast and reliable diagnosis is important for effective treatment .
Management and Treatment Approaches
Most uncomplicated cases of VVC can be managed with a variety of effective oral or topical antifungal treatments Brocklebank2013Sustr2020Nyirjesy2008. For recurrent cases, management includes identifying and eliminating predisposing factors, confirming the Candida species, and using induction therapy followed by maintenance suppressive therapy, often with fluconazole Sobel1987Sovianti2021Lines2020. However, fluconazole resistance and the need for species-specific treatment are growing concerns Sobel1987Sovianti2021. Guidelines recommend therapy tailored to the specific Candida species and patient needs Sustr2020Sobel1998Sovianti2021.
Challenges and Future Directions
Despite its high prevalence and impact on quality of life, VVC remains under-recognized in public health and research Willems2020Sobel1998. Recurrent VVC is particularly challenging to cure, especially with rising antifungal resistance Sobel1987Sovianti2021. There is ongoing research into the roles of the vaginal microbiome, host immune responses, and the development of vaccines or novel therapies Willems2020MacAlpine2024.
Conclusion
Vulvovaginal candidiasis is a widespread and impactful condition, primarily caused by Candida albicans but increasingly by non-albicans species. It is influenced by a range of host, behavioral, and environmental factors. While most cases are treatable, recurrent infections pose significant challenges, highlighting the need for continued research into prevention, diagnosis, and new treatment strategies Willems2020Sustr2020Gonçalves2016+4 MORE.
Sources and full results
Most relevant research papers on this topic